Our team in 2022, visiting our partners I-stem © Jean-Yves Seguy

Building AI to improve human health

In 2017, Nik, our CTO was diagnosed with a rare form of cancer with no options except for surgery. As a team working on advancing applied Artificial Intelligence (AI), we knew that we had the power to help find cures with this technology. Since then, our mission is to create and use AI to improve human health.

To achieve this mission, we develop our drug discovery platform, Zeptomics, and use it every day in to develop safe and effective drugs.

We are a passionate team, composed of highly talented individuals with a deep expertise in applied Artificial Intelligence and computational biology. Our HQ is located in Belgium, a country with top-notch pharmaceutical industries.

We value excellence, diversity, curiosity and kindness.

Our story

An interview with our CEO, Segolene
Kantify launches as an AI consultancy.
Nik, our CTO, just out of surgery
Nik, our CTO, gets diagnosed with a rare type of cancer.
An article about our work on predicting atrial fibrillation
We start our first projects where we use AI to develop biomarkers, with a focus on cardiology and histopathology.
Segolene, our CEO, presenting our results at a congress
We contribute to COVID-response by predicting public occupancy, and lay the groundworks for zeptomics.
A part of our team at a partner's labs
We initiate the multiple drug discovery projects in a variety of fields. We make significant advancements in our drug development algorithms.
Segolene, our CEO, presenting our advancements for local broadcast
We generate first promising in vitro data for a variety of projects. We continue to expand the capabilities of Zeptomics, and get funding from the Brussels region for our drug development efforts in Oncology. We stop our consultancy work to focus full-time on drug development.
Kick-off of our projects on Rare Neuromuscular Disorders
We continue to generate promising in vitro data, and generate our first promising in vivo data for multiple projects. We significantly continue to both expand the capabilities and performance of Zeptomics. We further expand our pipeline, and get funding from the European Commission for our drug development efforts in Rare Neuromuscular Disorders.
Segolene Martin, Kantify's CEO
Segolene Martin
Chief Executive Officer

Segolene is the CEO and co-founder of Kantify. In addition to her role at Kantify, Segolene is a board member at the Brussels Lifetech Cluster, and was until 2021 the Belgian Ambassador of Women in AI and selved on the Global Partnership on AI board until 2023.

Segolene was nominated Young ICT Lady of Belgium, AI Personality of the Year in 2019, and was a winner of the InspiringFifty contest for women in tech. She also received the Business Trophy from the Cercle Montaigne.

Segolene has a Master's in Public Affairs and an MBA, both earned cum laude. Before founding Kantify, she worked in innovation, regulation, and public affairs, holding various management positions.

Nik Subramanian, Kantify's CTO
Nik Subramanian
Chief Technology Officer

Nik is the CTO and co-founder of Kantify. Nik developed the early AI models and solutions in the field of digital health and drug discovery, and has continued to lead the technical developments at Kantify.

Nik has an Executive Master's in Finance (cum laude), a postgraduate degree in Management, and a Master's in Political and Social Sciences (magna cum laude). Before founding Kantify, he served as the director of operations for a large B2B group, managing over 1000 people and a revenue of over €300 million.

Nicolas Maignan, Kantify's COO
Nicolas Maignan
Chief Operating Officer

Nicolas is the Chief Operating Officer of Kantify. Nicolas joined Kantify almost at company inception.

He holds a Masters degree in Engineering from Institut National Polytechnique of Grenoble. Nicolas has successfully been coordinating many of our technology developments and drug discovery projects. He has a deep expertise of AI model research, development and deployment using a variety of data sources for different uses cases in drug discovery.